Literature DB >> 31356578

Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation.

Irena Míková1, Magdaléna Neřoldová2, Jaroslav A Hubáček2, Dana Dlouhá2, Milan Jirsa2, Eva Honsová3, Eva Sticová3, Věra Lánská4, Julius Špičák1, Pavel Trunečka1.   

Abstract

BACKGROUND: The rs58542926 polymorphism in transmembrane 6 superfamily member 2 (TM6SF2) is a genetic factor predisposing to nonalcoholic fatty liver disease. We aimed to explore the effect of recipient and donor TM6SF2 rs58542926 genotypes on liver graft fat content after liver transplantation.
METHODS: Steatosis was evaluated in liver biopsies from 268 adult recipients. The influence of recipient and donor TM6SF2 genotypes, patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 genotypes, and nongenetic factors on the steatosis grade assessed 6-30 months after transplantation was analyzed by ordinal logistic regression.
RESULTS: The presence of the TM6SF2 c.499A allele in the donor (P = 0.014), PNPLA3 c.444G allele in the donor (P < 0.001), posttransplant body mass index (P < 0.001), and serum triglycerides (P = 0.047) independently predicted increased liver fat content on multivariable analysis, whereas noncirrhotic liver disease, as an indication for liver transplantation, was associated with lower risk of steatosis (P = 0.003). The effects of the donor TM6SF2 A and PNPLA3 G alleles were additive, with an odds ratio of 4.90 (95% confidence interval, 2.01-13.00; P < 0.001), when both minor alleles were present compared with an odds ratio of 2.22 (95% confidence interval, 1.42-3.61; P = 0.002) when only one of these alleles was present.
CONCLUSIONS: The donor TM6SF2 c.499A allele is an independent risk factor of liver graft steatosis after liver transplantation that is additive to the effects of donor PNPLA3 c.444G allele.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31356578     DOI: 10.1097/TP.0000000000002876

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.

Authors:  Amedeo Lonardo; Alessandro Mantovani; Salvatore Petta; Amedeo Carraro; Christopher D Byrne; Giovanni Targher
Journal:  Nat Rev Endocrinol       Date:  2022-07-15       Impact factor: 47.564

2.  Liver transplantation in the era of non-alcoholic fatty liver disease/metabolic (dysfunction) associated fatty liver disease: the dilemma of the steatotic liver graft on transplantation and recipient survival.

Authors:  Seren M Gedallovich; Daniela P Ladner; Lisa B VanWagner
Journal:  Hepatobiliary Surg Nutr       Date:  2022-06       Impact factor: 8.265

3.  Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis.

Authors:  Pablo Gabriel-Medina; Roser Ferrer-Costa; Francisco Rodriguez-Frias; Andreea Ciudin; Salvador Augustin; Jesus Rivera-Esteban; Juan M Pericàs; David Martinez Selva
Journal:  Biomedicines       Date:  2022-04-28

Review 4.  Importance of genetic polymorphisms in liver transplantation outcomes.

Authors:  Tomislav Kelava; Petra Turcic; Antonio Markotic; Ana Ostojic; Dino Sisl; Anna Mrzljak
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

5.  Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation.

Authors:  Denisa Erhartova; Monika Cahova; Helena Dankova; Marie Heczkova; Irena Mikova; Eva Sticova; Julius Spicak; Ondrej Seda; Pavel Trunecka
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

Review 6.  Metabolic associated fatty liver disease: Addressing a new era in liver transplantation.

Authors:  Madeleine G Gill; Avik Majumdar
Journal:  World J Hepatol       Date:  2020-12-27

Review 7.  Genetic and Life Style Risk Factors for Recurrent Non-alcoholic Fatty Liver Disease Following Liver Transplantation.

Authors:  Speranta Iacob; Susanne Beckebaum; Razvan Iacob; Cristian Gheorghe; Vito Cicinnati; Irinel Popescu; Liana Gheorghe
Journal:  Front Nutr       Date:  2022-01-14

Review 8.  Growing challenge of post-liver transplantation non-alcoholic fatty liver disease.

Authors:  Maria Styliani Kalogirou; Olga Giouleme
Journal:  World J Transplant       Date:  2022-09-18

9.  Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study.

Authors:  Ahad Eshraghian; Elham Moasser; Negar Azarpira; Mohammad Reza Fattahi; Saman Nikeghbalian; Seyed Ali Malek-Hosseini; Bita Geramizadeh
Journal:  BMC Gastroenterol       Date:  2021-12-07       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.